Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)

被引：1
|
作者：
Rodon, Jordi [1 ,2 ]
Shapiro, G., I
Bedell, C.
Kwak, E. L.
Baselga, J.
Brana, I
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 09期
关键词：
D O I：
10.1158/1078-0432.CCR-15-0185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2192 / 2192
页数：1
相关论文
共 50 条
  • [1] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Shapiro, Geoffrey I.
    Rodon, Jordi
    Bedell, Cynthia
    Kwak, Eunice L.
    Baselga, Jose
    Brana, Irene
    Pandya, Shuchi S.
    Scheffold, Christian
    Laird, A. Douglas
    Nguyen, Linh T.
    Xu, Yi
    Egile, Coumaran
    Edelman, Gerald
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 233 - 245
  • [2] Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in CombinationWith Erlotinib in Patients With Solid Tumors
    Soria, Jean-Charles
    LoRusso, Patricia
    Bahleda, Ratislav
    Lager, Joanne
    Liu, Li
    Jiang, Jason
    Martini, Jean-Francois
    Mace, Sandrine
    Burris, Howard
    ONCOLOGIST, 2015, 20 (03): : 245 - 246
  • [3] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
    Moldovan, C.
    Soria, J.
    LoRusso, P.
    Guthrie, T.
    Song, C.
    Nguyen, L. T.
    Martini, J.
    Infante, J. R.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
    Faulkner, Neil
    LoRusso, Patricia M.
    Guthrie, Tina
    Soria, Jean-Charles
    Bahleda, Ratislav
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Massard, Christophe
    Van Leeuwen, Barbara
    Martini, Jean-Francois
    Scheffold, Christian
    Burns, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [5] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors
    Wheler, Jennifer J.
    Traynor, Anne M.
    Bailey, Howard H.
    Alta, Steven
    Falchook, Gerald S.
    Laird, A. Douglas
    Linh Nguyen
    Scheffold, Christian
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
    Traynor, A. M.
    Kurzrock, R.
    Bailey, H. H.
    Attia, S.
    Scheffold, C.
    van Leeuwen, B.
    Wu, B.
    Falchook, G. S.
    Moulder, S. L.
    Wheler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies
    Edelman, G.
    Bedell, C.
    Shapiro, G.
    Pandya, S. S.
    Kwak, E. L.
    Scheffold, C.
    Nguyen, L. T.
    Laird, A.
    Baselga, J.
    Rodon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
    Matulonis, Ursula
    Vergote, Ignace
    Backes, Floor
    Martin, Lainie P.
    McMeekin, Scott
    Birrer, Michael
    Campana, Frank
    Xu, Yi
    Egile, Coumaran
    Ghamande, Sharad
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 246 - 253
  • [9] Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
    Wheler, Jennifer
    Mutch, David
    Lager, Joanne
    Castell, Christelle
    Liu, Li
    Jiang, Jason
    Traynor, Anne M.
    ONCOLOGIST, 2017, 22 (04): : 377 - E37
  • [10] Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
    Brown, Jennifer R.
    Davids, Matthew S.
    Rodon, Jordi
    Abrisqueta, Pau
    Kasar, Siddha N.
    Lager, Joanne
    Jiang, Jason
    Egile, Coumaran
    Awan, Farrukh T.
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3160 - 3169
12345